IVABRADINE HYDROCHLORIDE Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Ivabradine Hydrochloride, and what generic alternatives are available?
Ivabradine Hydrochloride is a drug marketed by Annora Pharma, Ingenus Pharms Llc, and Zydus Pharms. and is included in three NDAs.
The generic ingredient in IVABRADINE HYDROCHLORIDE is ivabradine hydrochloride. There are nine drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the ivabradine hydrochloride profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Ivabradine Hydrochloride
A generic version of IVABRADINE HYDROCHLORIDE was approved as ivabradine hydrochloride by ANNORA PHARMA on October 5th, 2022.
Summary for IVABRADINE HYDROCHLORIDE
US Patents: | 0 |
Applicants: | 3 |
NDAs: | 3 |
Raw Ingredient (Bulk) Api Vendors: | 105 |
Clinical Trials: | 79 |
Patent Applications: | 224 |
Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for IVABRADINE HYDROCHLORIDE |
DailyMed Link: | IVABRADINE HYDROCHLORIDE at DailyMed |
Recent Clinical Trials for IVABRADINE HYDROCHLORIDE
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Second Affiliated Hospital of Guangzhou Medical University | Phase 4 |
Uniformed Services University of the Health Sciences | Phase 4 |
The Young Investigator Group of Cardiovascular Research | Phase 3 |
Anatomical Therapeutic Chemical (ATC) Classes for IVABRADINE HYDROCHLORIDE
Paragraph IV (Patent) Challenges for IVABRADINE HYDROCHLORIDE
Tradename | Dosage | Ingredient | Strength | NDA | ANDAs Submitted | Submissiondate |
---|---|---|---|---|---|---|
CORLANOR | Tablets | ivabradine hydrochloride | 5 mg and 7.5 mg | 206143 | 6 | 2019-10-15 |